Mild To Moderate Asthma clinical trials

Explore recruiting mild to moderate asthma clinical trials.

Recruiting mild to moderate asthma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Mild To Moderate Asthma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase II, multinational, multicentre, double-blind, randomised, active-controlled, 3-way cross-over study to evaluate the therapeutic equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a versus CHF5993 pMDI 100/6/12.5 µg HFA-134a in subjects with mild to moderate asthma. [TRECONY]

Slovakia, Czechia, Romania, Latvia, Germany, Hungary +2 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1b, Double-Blind Study to Investigate Safety, Tolerability, Pharmacokinetics, Efficacy, and Pharmacodynamics of Single Dose of ATI-052 in Participants with Mild to Moderate Asthma

Germany

Human Pharmacology (Phase I)- Other EU CTIS Study details

Phase 1, Randomized, Double-blind, Placebo-Controlled, First-in-Human Single Ascending Dose Study in Healthy Participants to Assess the Safety, Tolerability, and Pharmacokinetics of JNJ-95597528 and a Proof of Mechanism Study in Participants with Mild to Moderate Asthma

Germany, Belgium

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase 1 Study to Investigate the Safety and Tolerability of the Study Drug GB-0895 in Mild to Moderate Asthma Patients or Single Dose in Chronic Obstructive Pulmonary Disease (COPD)

Germany

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma

Belgium

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Prospective, randomised, double-blind, placebo-controlled multicenter clinical trial to evaluate efficacy and safety of sublingual immunotherapy in patients with rhinitis/rhinoconjunctivitis with or without mild to moderate asthma, allergic to Dermatophagoides pteronyssinus and/or Dermatophagoides farinae_MM09-SLG-058

Spain, Portugal

Therapeutic confirmatory (Phase III) EU CTIS Study details

Mild To Moderate Asthma trials by city

Mild To Moderate Asthma in Toronto Mild To Moderate Asthma in Vancouver Mild To Moderate Asthma in Montreal Mild To Moderate Asthma in Calgary Mild To Moderate Asthma in Edmonton Mild To Moderate Asthma in Ottawa Mild To Moderate Asthma in Winnipeg Mild To Moderate Asthma in Quebec City Mild To Moderate Asthma in Hamilton Mild To Moderate Asthma in Kitchener Mild To Moderate Asthma in London Mild To Moderate Asthma in Halifax Mild To Moderate Asthma in New York Mild To Moderate Asthma in Los Angeles Mild To Moderate Asthma in Chicago Mild To Moderate Asthma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease